热烈祝贺我司客户又一篇SCI文章被国际期刊收录

祝贺我司客户的优质研究成果被国际期刊《Clinical Rheumatology》收录

该文章时所食用的下述ELISA化学药品盒均购自我发展司。

Human IL-34 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)

Human TNF-a  ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)

Human IL-6 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)

Human IL-8 ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)

Human MMP-3  ELISA KIT(Xinfan Biotechology Co.,Ltd,shanghai，China)

信帆怪物是一种家专业的elisa免疫化学试剂盒销量商,销量各式出口国內公司的elisa免疫化学试剂盒。

在elisa免疫实验试剂盒,人们提高*的产品品质提高,专业性的新技术回答,用心仔細的售后客服提供服务,是全国数家教育科研单位和高职高专院校的免疫实验试剂盒供应商。

信帆海洋微生态学从推出至今已有，具备着许多年化学药品业务领域的生产制造、海洋微生态学化学药品和消售經驗，目前为止就已经成长期为中国面积巨大的化学药品生产制造、海洋微生态学化学药品和消售的綜合性中小企业，一直都为科研课题事情者助力器。我们公司遗憾您的远道而来！ 

该论文标题： Predictors of response to TNFα antagonist therapy in Chinese rheumatoid arthritis
Clinical Rheumatology

期刊号：Issue 7, pp 1203–1210

老师在论文后期编辑过程中与我们积极互动，信帆生物给予了支持，最终顺利被《Clinical Rheumatology》录用。

 以下是老师论文中使用我司产品的截图

热烈祝贺上海信帆客户又一篇SCI文章被国际期刊收录
《Clinical Rheumatology》期刊介绍：
Clinical Rheumatology is an international journal devoted to publishing in the English language original clinical investigation and research in the general field of rheumatology with accent on clinical aspects at postgraduate level. Studies carried out anywhere in the world will be considered the basic criterion for acceptance being the medical and scientific standard of the work described.

文章介绍

This study aimed to investigate the clinical, immunological, and radiologic predictors of response to tumor necrosis factor (TNF)-α antagonist therapy in Chinese rheumatoid arthritis (RA). Ninety RA patients were divided into two groups according to their responsiveness to TNF-α antagonist therapy at 1 month: group A (responders) and group B (non-responders). After 3 months of therapy, all the 90 patients were re-assessed and re-divided into another two groups: group C (responders) and group D (non-responders). Serum samples and clinical characteristics as well as radiographic features were collected at baseline, first month, and third month post-initial administration of TNF-α antagonist. Serum TNF-α, interleukin (IL)-6, IL-8, IL-34, and matrix metalloproteinase (MMP)-3 were measured by enzyme-linked immunosorbent assay (ELISA). Disease activity and Sharp score were evaluated. (1) Comparisons between groups A and B: subjects in group A showed a lower level of erythrocyte sedimentation rate (ESR) and a higher level of albumin (ALB) at baseline than that of group B (p < 0.05). The cutoff value of ALB for prediction was ≥34.9 g/l and that of ESR was ≤55.5 mm/h. (2) Comparisons between groups C and D: group C showed lower levels of ESR, health assessment questionnaire (HAQ), and IL-34 at baseline (p < 0.05). The threshold for prediction were as follows: ESR ≤60 mm/h, HAQ ≤1.3125, and IL-34 ≤194.12 pg/ml. (3) The serum cytokines were positively correlated with C-reactive protein (CRP) and disease activity index, while ALB was negatively correlated with CRP and disease activity. Baseline ALB ≥34.9 g/l or ESR ≤55.5 mm/h might predict a good response at 1-month treatment of TNF-α antagonist, while baseline ESR ≤60 mm/h, HAQ ≤1.3125, and IL-34 ≤194.12 pg/ml might predict a good response at 3-month treatment.

祝贺上海信帆生物ELISA试剂盒被高分国际期刊收录